Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in Jordan has been on the rise in recent years.
Customer preferences: Patients in Jordan have been increasingly seeking out Anti-Rheumatic Drugs due to the growing prevalence of rheumatic diseases in the country. Rheumatoid arthritis, for instance, is estimated to affect around 1% of the population in Jordan. Additionally, the aging population and changing lifestyles have contributed to the increasing demand for these drugs.
Trends in the market: The Anti-Rheumatic Drugs market in Jordan has been witnessing a shift towards biologic drugs. Biologics have been gaining popularity due to their effectiveness in treating rheumatic diseases and reducing the need for surgery. The market has also seen an increase in the use of combination therapy, where patients are prescribed multiple drugs to achieve better outcomes.
Local special circumstances: Jordan has a well-established healthcare system that provides affordable access to medications. The government has been making efforts to increase the availability of Anti-Rheumatic Drugs in the country through initiatives such as the Essential Medicines List (EML). The EML is a list of medications that are deemed essential for the treatment of common diseases and are made available to the public at subsidized prices.
Underlying macroeconomic factors: The Jordanian economy has been growing steadily in recent years, with a focus on diversifying the economy and attracting foreign investment. The healthcare sector has been identified as a priority area for development, with the government investing in infrastructure and healthcare services. This has contributed to the growth of the Anti-Rheumatic Drugs market in the country.In conclusion, the increasing demand for Anti-Rheumatic Drugs in Jordan can be attributed to the growing prevalence of rheumatic diseases, changing lifestyles, and an aging population. The shift towards biologic drugs and combination therapy is a trend that is expected to continue. The government's efforts to increase access to medications through initiatives such as the EML have also contributed to the growth of the market. The overall macroeconomic growth of the country has provided a favorable environment for the development of the healthcare sector, including the Anti-Rheumatic Drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
